The expression of oncogene products related to cell growth (c-erbB-2, c-myc, ras p21, EGFR) was investigated in benign (15 cases) and malignant breast lesions (20 cases) by means of immunohistochemistry using the avidin-biotin-peroxidase technique with polyclonal and monoclonal antibodies. The aim of this study was to evaluate the relationship between the staining positivity and various morphological and biological features, such as tumour type, grading, hormone receptor status and cell kinetic parameters.
In benign breast lesions, as expected, the kinetic parameters were low, both for Ki-67 and LI. All the specimens showed a diploid condition (the DI being equal to 1) and we found a limited degree of immunoreactivity for all the growth factors and oncogene products. In breast cancer we studied the distribution of immunohistochemical positivity for EGFR, c-erbB-2, c-myc, ras p21 and Ki-67, which was related to age, nodal status, ER and PgR receptor status, LI, DI and histopathological grading. A significant positive correlation was found both between ras p21 espression and nodal status and ERICA positivity. We observed a strong correlation between LI and Ki-67 and an inverse relation between Ki-67 and ER expression. These findings suggest the importance of studying the relationship between prognostic factors which may provide preoperative prediction in the biological behaviour of breast cancer, not only on biopsy specimens, but also on fine needle aspirates.
BonadonnaG.Conceptual and practical advances in the management of primary breast cancer. The Karnofsky Memorial Lecture. J Clin Oncol1989; 7: 1380–97.
2.
AlitaloK, SchwabM.Oncogene amplification in tumor cells. Adv Cancer Res1986; 47: 235–86.
3.
MaguireHCJr, GreeneMI. The neu (c-erbB-2) oncogene. Semin Oncol1989; 1: 148–55.
4.
ThorA, OhuchiN, Horan HandP, Ras gene alterations and enhanced levels of ras p21 expression in a spectrum of benign and malignant human mammary tissues. Lab Invest1986; 55: 603–15.
5.
EscotC, TheilletC, LidereauR, Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. Proc Natl Acad Sci USA1986; 83: 4834–8.
6.
LidereauR, CallahanR, DicksonC, PetersG, EscotC.Amplification of the int-2 gene in primary human breast tumours. Oncogene Res1988; 2: 285–91.
7.
DownwardJ, YardenY, MayesE, Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature1984; 307: 521–7.
8.
SainsburyJRC, FarndonJR, NeedhamGK, MalcolmAJ, HarrisAL. Epidermal-growth-factor receptor status as predictor of early recurrence and death from breast cancer. Lancet1987; i: 1399–402.
9.
Saccani JottiG.Prognostic factors in resectable breast cancer. Sem Oncol1991; 10–28.
10.
ClarkGM, McGuireWL. Prognostic value of oncogenes in breast cancer. In: BolleM, ChambazEM, VrousosC, eds Growth factors and oncogenes. Paris: Colloque INSERM, 1989; 190: 167–72.
11.
WaterfieldMD, MayerEL, StroobantP, A monoclonal antibody to the human epidermal growth factor receptor. J Cell Biochem1982; 20: 149–61.
12.
BergerMS, LocherGW, SaurerS, Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res1988; 48: 1238–43.
13.
GullickWJ, BergerMS, BennettPL, RothbardJB, WaterfieldMD. Expression of the c-erbB-2 protein in normal and transformed cells. Int J Cancer1987; 40: 246–54.
14.
van der VijverMJ, PeterseJL, MooiWJ, Neuprotein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med1988; 319: 1239–45.
15.
FurthME, DavisLJ, FleuredelysB.Monoclonal antibodies to the p21 products of the transforming gene of Harvey murine sarcoma virus and of the cellular ras gene family. J Virol1982; 43: 294–304.
16.
Horan HandP, ThorA, WunderlichD, Monoclonal antibodies of predefined specificity detect activated ras gene expression in human mammary and colon carinomas. Proc Natl Acad Sci USA1984; 81: 5227–31.
17.
GaspariniG, Dal FiorS, PozzaF, BevilacquaP.Correlation of growth fraction by ki-67 immunohistochemistry with histologic factors and hormone receptors in operable breast cancer. Breast Cancer Res Treat1989; 14: 329–36.
18.
GerdesJ, SchwabU, LemkeH, SteinH.Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with proliferation. Int J Cancer1983; 31: 13–20.
19.
World Health Organization. Histological typing of breast tumors, second edition. Am J Clin Pathol1982; 78: 506–16.
20.
BloomHJG, RichardsonWW. Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer1957; 11: 359–77.
21.
HsuSM, RaineL, FangerH.A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol1981; 75: 734–8.
22.
HsuSM, RaineL, FangerH.Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques. J Histochem Cytochem1981; 29: 577–80.
23.
DelarueJC, FriedmanS, MouriesseH, May-LevinL, Sancho-GarnierH, ContessoG.Epidermal growth factor receptor in human breast cancer: correlation with estrogen and progesterone receptors. Breast Cancer Res Treat1988; 11: 173–8.
24.
SilvestriniR, DaidoneMG, ValagussaP, Di FronzoG, MezzanotteG, BonadonnaG.Cell kinetics as a prognostic indicator in node negative breast cancer. Eur J Cancer Clin Oncol1989; 25: 1165–71.
25.
BeermanH, SmitVthbm, KluinPM, Flow cytometric analysis of DNA stemline heterogeneity in primary and metastatic breast cancer. Cytometry1991; 12: 147–54.
26.
TauchiK, HoriS, lothH, OsamuraRY, TokudaY, TajimaT.Immunohistochemical studies on oncogene products (c-erbB-2, EGFR, c-myc) and estrogen receptor in benign and malignant breast lesions. Virchows Archiv A Pathol Anat1989; 416: 65–73.
27.
MollerP, MechtersheimerG, Kaufmann, MoldenhauerG, MamburgF, NattfeldtT.Expression of epidermal growth factor receptor in benign and malignant primary tumours of the breast. Virchows Archiv A Pathol Anat1989; 414: 157–64.
28.
KamelOW, FranklinWA, RingusJC, MeyerJS. Thymidine labeling index and Ki-67 growth fraction in lesions of the breast. Am J Pathol1989; 134: 107–13.
29.
SpandidosDA, YiagnisisM, PapadimitriouK, FieldJK. Ras, c-myc and c-erbB-2 oncoproteins in human breast cancer. Anticancer Res1989; 9: 1385–94:
30.
WalkerRA, SeniorPV, JonesJL, CritchleyDR, VarleyJN. An immunohistochemical and in situ hybridization study of c-myc and c-erbB-2 expression in primary human breast carcinomas. J Pathol1989; 158: 97–105.
31.
GullickWJ, LoveSB, WrightC, C-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninsolved lymph nodes. Br J Cancer1991; 63: 434–8.
32.
BevilacquaP, GaspariniG, Dal FioreS, CorradiG.Immunocytochemical determination of epidermal growth factor receptor with monoclonal EGFR 1 antibody in primary breast cancer patients. Oncology1990; 47: 313–7.
33.
SainsburyJRC, MalcolmAY, AppletonDR, FarndonJR, HarrisA.Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer. J Clin Pathol1985; 38: 1225–8.
34.
FieldJK, SpandidosDA. The role of ras and myc oncogenes in human solid tumours and their relevance in diagnosis and prognosis. Anticancer Res1990; 10: 1–22.
35.
CrispinoS, BrennaA, ColomboD, Ki-67 labeling index in breast cancer. Tumori1989; 75: 567–62.
36.
WintzerHO, ZipfelJ, Schulte-MontingJ, HellerichU, Von KleistS.Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer1991; 67: 421–8.
37.
Di StefanoD, MingazziniPL, ScucchiL, DonnettiM, MarinozziV.A comparative study of histopathology, hormone receptors, peanut lectin binding, Ki-67 immunostaining and nuclear organizer region-associated proteins in human breast cancer. Cancer1991; 67: 463–71.
38.
AmadoriD, BonaguriC, NanniO, Cell kinetics and hormonal features in relation to pathological stage in breast cancer. Breast Cancer Res Treat1991; 18: 19–25.
39.
QuerzoliP, MarchettiE, BagniA, MarzdaA, GuidalbertoF, NenciI.Expression of p21 ras gene products in breast cancer relates to histological types and receptor and nodal status. Breast Cancer Res Treat1988; 12: 23–30.
40.
CzerniakB, ChenR, TuziakT, Expression of ras oncogene p21 protein in relation to regional spread of human breast carcinomas. Cancer1989; 63: 2008–13.
41.
SilvestriniR, DaidoneMG, GaspariniG.Cell kinetics as a persistent prognostic marker in node negative breast cancer. Cancer1985; 56: 1982–7.
42.
SilvestriniR, DaidoneMG, Di FronzoG, MozzavitoA, ValagussaP, BonadonnaG.Prognostic implication of labeling index versus estrogen receptors and tumor size in node negative breast cancer. Breast Cancer Res Treat1986; 7: 161–9.
43.
SilvestriniR, DaidoneMG, ValgussaP, Cell kinetics as a prognostic marker in locally advanced breast cancer. Cancer Treat Rep1987; 4: 375–9.
44.
SilvestriniR.Breast cancer: contribution of cell kinetics to prognosis and treatment. In: BrescianiF, LippmanRJ, RaynaudJP eds. Progress in Cancer Research and Therapy. Raven Press, 1988; 33: 388–93.
45.
NicholsonRI, McClellandRA, GeeJMW, Patient stratification for tamoxifen therapy based on cell biology. International Conference on: Long term anti-hormonal therapy for breast cancer. Lake Buena Vista, Florida, 1991, P 6, 21.
